Reach Us +1-504-608-2390
Changes In Bone Biological Markers With Treatment Of Pioglitazone In Iranian Diabetic Patients: No Relation To Polymorphism Of PPAR? (Pro12Ala) | 5785
ISSN: 2161-0495

Journal of Clinical Toxicology
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Changes in bone biological markers with treatment of pioglitazone in Iranian diabetic patients: No relation to polymorphism of PPAR? (Pro12Ala)

International Toxicology Summit & Expo

Fatemeh Namvaran

Posters: J Clinic Toxicol

DOI: 10.4172/2161-0495.S1.007

T he peroxisome proliferator-activated receptor γ (PPARγ) has important effects in insulin sensitivity, obesity and diabetes. Thiozolidendions improve insulin sensitivity by activating the PPARγ. Based on strong evidences, we expect increased fracture risk, and delayed fracture healing through thiozolidendions treatment. Our aim is to study any association between variation in bone biochemical markers and single nucleotide polymorphism (SNP) in PPARγ (pro12 Ala) and investigating if these genetic variant affect bone turn over markers in an Iranian diabetic population before and after treatment with pioglitazone. A total of 101 patients (T2D) were treated for 12 weeks with pioglitazone (15 mg/day). Bone Biological markers, osteocalcin and C-terminal telopeptide of type 1 collagen (ICTP) were measured before and after pioglitazone therapy. We genotyped 128 non- diabetic controls and 101 Type 2 diabetic patients as well. Pro12Ala polymorphism in PPARγ was done by Real Time PCR using TaqMan assay. There were statistically-significant differences in allele frequencies of Pro12Ala comparing controls with Type 2 diabetic subjects. Ala frequency was 7% vs. 3 %, p = 0.036, and genotypic frequencies of Pro/Ala were 5.94% vs 14.06%, p value = 0.04. There were significant differences in bone biological markers before and after pioglitazone therapy. Our findings could not reach to significant association between this polymorphism and bone turn over markers after pioglitazone treatment. We found that pioglitazone treatment caused significant changes in bone biological markers after treatment
Fatemeh Namvaran has completed his Ph.D at the age of 30 years from Tehran University of Medical Sciences, College of Medicine. She is working with Transplant Research Center, Shiraz University of Medical Sciences. She has published 10 papers in reputed journals